These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22706009)

  • 1. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world.
    Vella S; Schwartländer B; Sow SP; Eholie SP; Murphy RL
    AIDS; 2012 Jun; 26(10):1231-41. PubMed ID: 22706009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides.
    Martin JC; Hitchcock MJ; De Clercq E; Prusoff WH
    Antiviral Res; 2010 Jan; 85(1):34-8. PubMed ID: 19854224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Access to antiretroviral treatment in developing countries: Which financing strategies are possible?
    Beaulière A; Le Maux A; Trehin C; Perez F
    Rev Epidemiol Sante Publique; 2010 Jun; 58(3):171-9. PubMed ID: 20430553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inequalities in health: access to treatment for HIV/AIDS.
    Giuliano M; Vella S
    Ann Ist Super Sanita; 2007; 43(4):313-6. PubMed ID: 18209264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A brief history of antiretroviral therapy of HIV infection: success and challenges.
    Palmisano L; Vella S
    Ann Ist Super Sanita; 2011; 47(1):44-8. PubMed ID: 21430338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence as therapeutic citizenship: impact of the history of access to antiretroviral drugs on adherence to treatment.
    Nguyen VK; Ako CY; Niamba P; Sylla A; Tiendrébéogo I
    AIDS; 2007 Oct; 21 Suppl 5():S31-5. PubMed ID: 18090265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free care at the point of service delivery: a key component for reaching universal access to HIV/AIDS treatment in developing countries.
    Souteyrand YP; Collard V; Moatti JP; Grubb I; Guerma T
    AIDS; 2008 Jul; 22 Suppl 1():S161-8. PubMed ID: 18664948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral drugs.
    De Clercq E
    Curr Opin Pharmacol; 2010 Oct; 10(5):507-15. PubMed ID: 20471318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future management of treatment failure in low- and middle-income countries.
    Boyd MA
    Curr Opin HIV AIDS; 2010 Jan; 5(1):83-9. PubMed ID: 20046152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Brazilian experiment: HIV drugs for all.
    Flaer PJ; Younis MZ
    J Health Care Finance; 2009; 36(2):90-6. PubMed ID: 20499725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to optimize HIV treatment outcomes in resource-limited settings.
    Nakanjako D; Colebunders R; Coutinho AG; Kamya MR
    AIDS Rev; 2009; 11(4):179-89. PubMed ID: 19940945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [History and the development of the studies on HIV and AIDS].
    Rogala M
    Wiad Lek; 2011; 64(4):255-9. PubMed ID: 22533148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral therapy and resistance to antiretroviral drugs.
    Lange JM; van Leeuwen R
    Ethiop Med J; 2002 Apr; 40 Suppl 1():51-75. PubMed ID: 12802831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction: the realities of antiretroviral therapy rollout: overcoming challenges to successful programmatic implementation.
    Ojikutu B
    J Infect Dis; 2007 Dec; 196 Suppl 3():S445-8. PubMed ID: 18181692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and challenges of antiretroviral research and therapy.
    Esté JA; Cihlar T
    Antiviral Res; 2010 Jan; 85(1):25-33. PubMed ID: 20018390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.